DNMT1 and myelodysplastic syndrome: Similarly, treatment with Nexturastat A (NextA), an HDAC6i, also increased MHC-I expression, which was further increased in combination with 5-azacytidine (5-aza), a DNMT inhibitor already approved for treatment of high-risk myelodysplastic syndrome (MDS) (100).